Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past year. As of today (2026-09-22), Cytophage Technologies's 1-Year Sortino Ratio is -3.46.
Cytophage Technologies (OTCPK:CPTCF) 1-Year Sortino Ratio Explanation
The 1-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by the standard deviation of negative returns over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.
Cytophage Technologies 1-Year Sortino Ratio Related Terms
CPTCF vs VRTX, REGN, RVMD: 1-Year Sortino Ratio Comparison
For the Biotechnology subindustry, Cytophage Technologies's 1-Year Sortino Ratio, along with its competitors' market caps and 1-Year Sortino Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytophage Technologies 1-Year Sortino Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cytophage Technologies's 1-Year Sortino Ratio distribution charts can be found below:
* The bar in red indicates where Cytophage Technologies's 1-Year Sortino Ratio falls into.
Cytophage Technologies 1-Year Sortino Ratio Calculation
The 1-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio over the past year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 1-Year Sortino Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the downside risks over one year.
A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.
Cytophage Technologies (CPTCF) has a 1-Year Sortino Ratio of -3.46 as of Sep. 22, 2026. 1-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk. View historical data for Cytophage Technologies and its competitors.
Is Cytophage Technologies' 1-Year Sortino Ratio too high?
Cytophage Technologies' current 1-Year Sortino Ratio is -3.46. Overall, Cytophage Technologies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cytophage Technologies' 1-Year Sortino Ratio compare to VRTX and REGN?
Cytophage Technologies' 1-Year Sortino Ratio of -3.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sortino Ratio for a Biotechnology company?
A good 1-Year Sortino Ratio depends on the Biotechnology industry context. However, 1-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sortino Ratio mean?
A high 1-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk. View historical data for Cytophage Technologies and its competitors. Cytophage Technologies's current 1-Year Sortino Ratio is -3.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytophage Technologies stock overvalued right now?
Cytophage Technologies (CPTCF) has a current 1-Year Sortino Ratio of -3.46. The current 1-Year Sortino Ratio is -3.46. Cytophage Technologies' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sortino Ratio calculated?
1-Year Sortino Ratio is calculated from a company's financial statements. For Cytophage Technologies (CPTCF), the current 1-Year Sortino Ratio is -3.46 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cytophage Technologies Ltd is a Canadian biotechnology company that develops bacteriophage-based products using molecular genetics and synthetic biology. Bacteriophages are viruses that infect and kill specific bacteria, and the company engineers them to target bacterial pathogens, including antibiotic-resistant strains. Its programs address three main areas: animal health, human health, and food safety and security. In animal health, Cytophage is developing treatments intended to reduce bacterial disease and antibiotic use in livestock and poultry production. For human health, it is pursuing phage therapies against drug-resistant infections. Its food safety work focuses on products that control bacterial contamination in food production and processing. The company is based in Winnipeg, Manitoba, Canada, and operates as a research and development-stage enterprise, generating revenue primarily through research collaborations, licensing arrangements, and grant funding rather than from commercial product sales.
18GF Score
Get the complete analysis for CPTCF
1-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPTCF has been successfully added to your 
